Insulet Corp. (PODD) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Insulet’s revenue went from $367M in fiscal 2016 to $2.7B in fiscal 2025, growth of about 24.9% a year.
Net income in fiscal 2025 was $247M, a net margin of 9.1%; the best year in this period was 2024 with $418M.
Over the twelve months to September 30, 2026, revenue was $3.2B and net income $429M.
Free cash flow was $378M in fiscal 2025 and positive in 3 of the 10 years shown.
The diluted share count rose 26% over the period (dilution).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.2B | $2.7B | $2.1B | $1.7B | $1.3B | $1.1B | $904M | $738M | $564M | $464M | $367M |
| Gross profit | $2.3B | $1.9B | $1.4B | $1.2B | $806M | $752M | $582M | $480M | $370M | $277M | $211M |
| Operating income | $588M | $474M | $309M | $220M | $38M | $126M | $52M | $50M | $27M | -$7M | -$11M |
| Net income | $429M | $247M | $418M | $206M | $5M | $17M | $7M | $12M | $3M | -$27M | -$29M |
| EPS (diluted) | $6.13 | $3.48 | $5.78 | $2.94 | $0.07 | $0.24 | $0.10 | $0.19 | $0.05 | $-0.46 | $-0.48 |
| R&D | $360M | $301M | $220M | $205M | $180M | $160M | $147M | $132M | $95M | $76M | $56M |
| Revenue growth | — | +30.7% | +22.1% | +30.0% | +18.8% | +21.5% | +22.5% | +30.9% | +21.6% | +26.4% | +39.1% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $509M | $569M | $430M | $146M | $119M | -$68M | $84M | $98M | $36M | $41M | $16M |
| Capital spending | -$249M | -$192M | -$125M | -$76M | -$123M | -$112M | -$129M | -$164M | -$157M | -$74M | -$22M |
| Free cash flow | $260M | $378M | $305M | $70M | -$4M | -$180M | -$45M | -$65M | -$122M | -$32M | -$6M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $300M | $60M | $0 | $0 | — | — | — | — | — | — | — |
| Stock-based pay | $82M | $63M | $69M | $48M | $41M | $34M | $36M | $29M | $38M | $32M | $24M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $716M | $953M | $704M | $690M | $806M | $948M | $376M | $289M | $273M | $137M |
| Debt | — | $1.0B | $1.4B | $1.4B | $1.4B | $1.3B | $1.1B | $906M | $592M | $566M | $333M |
| Equity | — | $1.5B | $1.2B | $733M | $476M | $556M | $604M | $76M | $212M | $158M | $63M |
| Total assets | — | $3.2B | $3.1B | $2.6B | $2.3B | $2.0B | $1.9B | $1.1B | $929M | $817M | $457M |
| Shares (diluted) | 69M | 72M | 74M | 74M | 70M | 69M | 66M | 62M | 61M | 58M | 57M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 71.9% | 71.6% | 69.8% | 68.3% | 61.7% | 68.5% | 64.4% | 65.1% | 65.7% | 59.8% | 57.5% |
| Operating margin | 18.4% | 17.5% | 14.9% | 13.0% | 2.9% | 11.5% | 5.7% | 6.8% | 4.9% | -1.6% | -2.9% |
| Net margin | 13.4% | 9.1% | 20.2% | 12.2% | 0.4% | 1.5% | 0.8% | 1.6% | 0.6% | -5.8% | -7.9% |
| FCF margin | 8.2% | 14.0% | 14.7% | 4.1% | -0.3% | -16.4% | -5.0% | -8.8% | -21.6% | -7.0% | -1.7% |
| ROIC | — | 13.7% | 9.3% | 9.7% | 1.6% | 5.6% | 2.1% | 4.1% | 2.2% | -0.8% | -2.1% |
| ROE | — | 16.3% | 34.5% | 28.2% | 1.0% | 3.0% | 1.1% | 15.3% | 1.6% | -16.9% | -45.8% |
Frequently asked questions
What is Insulet’s annual revenue?
$2.7B in fiscal 2025 and $3.2B over the twelve months to September 30, 2026.
How much profit does Insulet make?
Net income was $247M in fiscal 2025 (net margin 9.1%).
Is Insulet’s revenue growing?
Yes: revenue rose 30.7% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.